Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

Item
http://www.wikidata.org/entity/Q43057273
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.Current therapy of myelodysplastic syndromesImportant genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Molecular dissection of the 5q deletion in myelodysplastic syndrome.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesRibosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53.Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup.Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
P2860

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

Item
http://www.wikidata.org/entity/Q43057273
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Changes in RPS14 expression le ...... s with chromosome 5q deletion.
@en
Changes in RPS14 expression le ...... s with chromosome 5q deletion.
@nl
type
label
Changes in RPS14 expression le ...... s with chromosome 5q deletion.
@en
Changes in RPS14 expression le ...... s with chromosome 5q deletion.
@nl
prefLabel
Changes in RPS14 expression le ...... s with chromosome 5q deletion.
@en
Changes in RPS14 expression le ...... s with chromosome 5q deletion.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Changes in RPS14 expression le ...... s with chromosome 5q deletion.
@en
P2093
P304
P31
P356
10.1111/J.1600-0609.2010.01473.X
P433
P478
P50
P577
P698